News from Flexiseq

The personal information you are providing will help us to deliver, develop and promote Flexiseq products. Submitting your details indicates that you have read and agreed to our privacy and cookie policy. You can read our policies here.


So, which Flexiseq is right for you? It’s the question we get asked the most.

Here’s our simple guide:

Flexiseq Osteoarthritis - £11.89 (30 g) £18.49 (50 g) £32.95 (100 g)

Flexiseq Active - £12.99 (50 g) £22.99 (100 g)

What is Flexiseq Osteoarthritis?

If you have diagnosed osteoarthritis, nothing but the best will do. That’s why Flexiseq Osteoarthritis is loaded with our max strength formulation, tested in clinical trials with the most demanding patients.

Flexiseq Osteoarthritis is clinically proven*, drug free relief from the pain and stiffness of osteoarthritis. A drug-free, sustainable solution to effectively relieve the pain and stiffness of osteoarthritic joints to keep you moving.

Flexiseq also comes in a smaller 30g pack size, with your smaller joints in mind. Whether you’re knitting, playing golf, tinkling the ivories or even packing a holiday bag, the Flexiseq “Handy Pack” is perfect for looking after your joints, on the go.

NEW Flexiseq Osteoarthritis (Max Strength) 100g pack size! The best option for those who use Flexiseq on multiple joints and offering a saving of over 10%** in the process! Pick up your pack exclusively from LloydsPharmacy today!

**price comparison based on the price of two packs of Flexiseq Osteoarthritis (Max Strength) 50g.

Download patient information leaflet

What is Flexiseq Active?

Flexiseq Active contains a lighter formulation of our original, drug free, joint lubricating technology, for active joints affected by everyday wear and tear.

Whether you are cycling to work, walking the hills, jogging with the dog or taking a weekend Zumba class, Flexiseq Active provides trusted relief from the pain and stiffness of joint wear and tear to keep you moving.

Download patient information leaflet

*Tested in Phase III Clinical Trials among mild to moderate osteoarthritis patients.
Conaghan P, et al. Current Medical Research & Opinion 2013, 1-13